Losartan (TGFβ2 inhibitor)-treated mdx mice (a commonly used mouse model of DMD) had high levels of myogenic factors with decreased expression of fibrogenic genes [31], opening up a potential treatment for DMD patients using the US Food and Drug Administration (FDA) approved drug—losartan. The gene discussed is TGFB2; the disease is Duchenne muscular dystrophy.